

DIASORIN: NEW PROPOSAL FOR RESOLUTION RELATED TO THE REMUNERATION OF THE BOARD OF STATUTORY AUDITORS

Saluggia, April 22, 2022 – With reference to the Shareholders' meeting called on April 29 2022, at 11.00 a.m., in a single calling, DiaSorin (FTSE MIB: DIA) announces that the Shareholder IP Investimenti e Partecipazioni S.r.l. filed today a new proposal for resolution related to the remuneration of the Board of Statutory Auditors under item no. 4.3. on the agenda, replacing the proposal previously filed by the same shareholder without amending all the other proposals related to the appointment of the Board of Directors in relation to items no. 3.1, 3.2 and 3.4 on the agenda (about the number of the members, the duration of their office and the remuneration of the Board).

The proposals for resolution filed by IP Investimenti e Partecipazioni S.r.l., as amended in the light of the new proposal, are available to the public at the Company's registered office, on the Company's website (www.diasoringroup.com, section "Governance"/ "Shareholders meetings"/"2022") and on the authorized storage mechanism used by the Company available on the website www.emarketstorage.com.

For additional information, please contact:

Riccardo Fava
Corporate Vice President Communication & Investor Relations
Tel: +39.0161.487988
riccardo.fava@diasorin.it

Emanuela Salvini
Investor Relator
Tel: +39.0161.487567
emanuela.salvini@diasorin.it

About DiaSorin

Headquartered in Italy and listed at the Italian Stock Exchange in the FTSE MIB Index, DiaSorin is a global leader in the In Vitro Diagnostic (IVD) field and is active since 2021 in the Life Science business. For over 50 years, the Company has been developing, producing and marketing reagent kits used by diagnostic laboratories worldwide.

The Group operates in 5 continents through 43 companies, 4 branches, 10 manufacturing facilities and 9 research and development centers. The extensive diagnostic testing and Life Science offer, made available through continuous investments in research, positions DiaSorin as the player with the broadest range of specialty tests available within the diagnostic market, and identifies the Group as the "Diagnostic Specialist". More info at www.diasoringroup.com